SapM 突变改良 BCG 疫苗:基因组、转录组与临床前安全性特征
本研究对 sapM::Tn 突变株与亲本 BCG Pasteur 进行基因组和转录组比较,并在免疫缺陷 SCID 小鼠中评估安全性。结果显示 sapM::Tn 突变株静脉给药后致病性与野生型 BCG 同样低,且接种后固有免疫控制更有效,导致产生 IFNγ 的 Th1 和 Tc1 细胞快速收缩。
要点
- sapM::Tn 突变株在 SCID 小鼠中致病性与 WT BCG 同样低。
- 接种后固有免疫对 sapM::Tn 疫苗菌的控制优于 WT BCG。
- sapM::Tn 接种后 IFNγ 产生型 Th1 和 Tc1 细胞快速收缩。
核心结论
- 通过 sapM 突变进一步减毒 BCG 可获得在 TB 感染时长期存活改善的活减毒疫苗。
研究设计与样本
- 对 sapM::Tn 突变株与亲本 BCG Pasteur 进行基因组和转录组表征。
- 在免疫缺陷 SCID 小鼠中静脉给药评估致病性。
- 接种后研究疫苗菌清除及 IFNγ 产生型 Th1 和 Tc1 细胞反应。
主要发现
- sapM::Tn 突变株静脉给药至免疫缺陷 SCID 小鼠后致病性与 WT BCG 同样低,通过安全性测试。
- 接种后固有免疫对 sapM::Tn 疫苗菌的控制比 WT BCG 更有效。
- sapM::Tn BCG 接种后 IFNγ 产生型 Th1 和 Tc1 细胞快速收缩。
临床怎么用
- 对疫苗菌固有免疫控制的分析可能为其他在研活减毒 TB 疫苗提供参考。
- SapM 突变可作为开发更具保护性活减毒 TB 疫苗的策略进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccine shows variable efficacy in protection against adult tuberculosis (TB). Earlier, we have described a BCG mutant vaccine with a transposon insertion in the gene coding for the secreted acid phosphatase SapM, which led to enhanced long-term survival of vaccinated mice challenged with TB infection. To facilitate development of this mutation as part of a future improved live attenuated TB vaccine, we have now characterized the genome and transcriptome of this sapM::Tn mutant versus parental BCG Pasteur. Furthermore, we show that the sapM::Tn mutant had an equal low pathogenicity as WT BCG upon intravenous administration to immunocompromised SCID mice, passing this important safety test. Subsequently, we investigated the clearance of this improved vaccine strain following vaccination and found a more effective innate immune control over the sapM::Tn vaccine bacteria as compared to WT BCG. This leads to a fast contraction of IFNγ producing Th1 and Tc1 cells after sapM::Tn BCG vaccination. These findings corroborate that a live attenuated vaccine that affords improved long-term survival upon TB infection can be obtained by a mutation that further attenuates BCG. These findings suggest that an analysis of the effectiveness of innate immune control of the vaccine bacteria could be instructive also for other live attenuated TB vaccines that are currently under development, and encourage further studies of SapM mutation as a strategy in developing a more protective live attenuated TB vaccine.
引用
- Festjens N, Vandewalle K, Houthuys E, et al. SapM mutation to improve the BCG vaccine: Genomic, transcriptomic and preclinical safety characterization. Vaccine. 2019. PMID: 31122861. doi:10.1016/j.vaccine.2019.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。